spacer
home > white papers > How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction - Temptime Corporation
WHITE PAPERS
logo_Temptime_C.png

Temptime Corporation

phone +1 973 984 6009
email info@temptimecorp.com
web http://temptimecorp.com/edge-wireless-connected-sensors/
email 116 The American Road, Morris Plains, 07950, New Jersey

How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction

The specialty pharmacy industry could reduce costs by $27.5 million annually (product and call center staff costs only) if visual temperature indicators were used as decision-making tools to determine if medicine should be used or returned when patients suspect heat damage. In addition, 97% of patients surveyed, who received medicine from specialty pharmacies with a visual temperature indicator included in the package, agree that they would want an indicator in all shipments and 95% agree the indicator increased their confidence in the medicines received.
How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Kallik’s Release 6 sets new benchmarks for speed, accuracy and efficiency

Tamworth, UK – 15 June 2019 – Global provider of labelling and artwork management solutions, Kallik, is launching an update to its AMS360 solution – its Release 6, transforming the experience of the business user, whilst defining new benchmarks for speed, accuracy, and efficiency of global labelling and artwork processes.
More info >>


White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>


Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement